Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
A new Phase 1 study looking at psilocybin in combination with psychological support as a treatment for females with anorexia nervosa has shown positive results.
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
Dimethyltryptamine (DMT) is a naturally occurring psychedelic compound found in many plants and some animals.
Alcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use...
As hypothesised with cannabis, could the ‘entourage effect’ play a role in the therapeutic effects of psilocybin mushrooms?
MGC Pharmaceuticals has received permission to import psilocybin into Slovenia.
Kernel has published results from its Cybin-sponsored neuroimaging study which show the ability of Kernel’s Flow1 system to capture and analyse brain changes induced by psychedelics.
Adaptogens are herbs, roots and other plant substances (like mushrooms) that help our bodies manage stress and restore balance after a stressful situation.
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
As their 300-gram MDMA shipment got to the border, PharmAla Biotech found themselves in a sticky situation.